ciprofloxacin has been researched along with azd0914 in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
Authors | Studies |
---|---|
Cole, M; Fredlund, H; Jacobsson, S; Ringlander, J; Unemo, M; Wiggins, C | 1 |
Andrews, B; Basarab, GS; Doig, P; Ehmann, DE; Fan, J; Gao, N; Kern, G; Mills, SD; Mueller, J; Palmer, T; Shapiro, AB; Sriram, S; Thresher, J; Walkup, GK | 1 |
Alm, RA; Le, WJ; Li, S; Liu, YR; Mueller, JP; Rice, PA; Su, XH; Wan, C; Wang, BX | 1 |
Aanensen, D; Ahlstrand, J; Cole, MJ; Day, M; Golparian, D; Jacobsson, S; Sánchez-Busó, L; Unemo, M | 1 |
Grad, YH; Mortimer, TD; Rubin, DH | 1 |
1 trial(s) available for ciprofloxacin and azd0914
Article | Year |
---|---|
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Europe; Gonorrhea; Humans; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds | 2021 |
4 other study(ies) available for ciprofloxacin and azd0914
Article | Year |
---|---|
High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Europe; Fluoroquinolones; Humans; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds | 2015 |
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Topics: Anti-Bacterial Agents; Barbiturates; Ciprofloxacin; Clinical Trials as Topic; DNA; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gene Expression; Humans; Isoxazoles; Morpholines; Mutation; Neisseria gonorrhoeae; Oxazolidinones; Species Specificity; Spiro Compounds; Topoisomerase II Inhibitors | 2015 |
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Ceftriaxone; Ciprofloxacin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Gene Expression; Gonorrhea; Humans; Isoxazoles; Male; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; Tetracycline; Topoisomerase II Inhibitors; Urethritis | 2016 |
Neisseria gonorrhoeae diagnostic escape from a gyrA-based test for ciprofloxacin susceptibility and the effect on zoliflodacin resistance: a bacterial genetics and experimental evolution study.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; Gonorrhea; Humans; Neisseria gonorrhoeae | 2023 |